Vaxelis Market Report 2026

Vaxelis Market Overview

• The Vaxelis market growth in the historic period has been driven by expansion of childhood immunization coverage, inclusion of combination vaccines in public health programs • Market expansion is supported by expansion of global vaccination initiatives, rising demand for simplified immunization regimens • Growth Driver: Rise In Pediatric Population Driving Market Growth Due To Increasing Demand For Childhood Vaccination Programs • North America was the largest region in 2025.

What Is Covered Under Vaxelis Market?

Vaxelis is a six-in-one vaccine that helps prevent diphtheria, tetanus, whooping cough, polio, haemophilus influenzae type B infections, and hepatitis B. It is primarily used in infants and children as part of standard vaccination programs. The main indications on the vaxelis include pertussis, diphtheria, and tetanus. Pertussis is a highly contagious respiratory infection caused by bordetella pertussis, characterized by severe coughing fits that can lead to difficulty breathing. Vaxelis provides protection against pertussis by stimulating the immune system to prevent infection and reduce the severity of symptoms in children. It is distributed through various channels such as hospitals, retail pharmacies, and government supplies and used by several end users such as hospitals, clinics, ambulatory care, and home care.

What Is The Vaxelis Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of global vaccination initiatives, rising demand for simplified immunization regimens, increasing investments in vaccine innovation, growing focus on supply chain resilience, expansion of immunization access in emerging markets. Major trends in the forecast period include increasing adoption of combination vaccines, rising emphasis on pediatric immunization programs, growing demand for single-dose multivalent vaccines, expansion of national vaccination schedules, enhanced focus on cold-chain vaccine management.

Global Vaxelis Market Segmentation

1) By Indication: Pertussis, Diphtheria, Tetanus 2) By Distribution Channel: Hospitals, Retail Pharmacies, Government Supplies 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Vaxelis Market?

The rise in pediatric population is expected to drive the growth of the vaxelis market going forward. The pediatric population refers to the demographic group of patients spanning from birth through adolescence. The rising pediatric population is driven by improved healthcare, nutrition, maternal care, reduced infant mortality, and increased awareness of child health and vaccination efforts. Vaxelis protects children against six serious diseases in one convenient vaccine, reducing the burden of multiple immunizations. For instance, in December 2024, according to the Child Stats, a US-based federal interagency forum for child and family statistics, in 2022, the United States had 72.5 million children, and the number is projected to increase to 78.2 million by 2050. Therefore, the rise in pediatric population is driving the growth of vaxelis industry. The increase in the prevalence of hepatitis B cases is expected to propel the growth of the vaxelis market going forward. Hepatitis B refers to a viral infection caused by the hepatitis B virus (HBV) that affects the liver, potentially leading to both acute and chronic diseases such as liver cirrhosis and liver cancer. The growing number of hepatitis B cases is due to factors like insufficient vaccination, weak healthcare systems, high-risk activities such as needle sharing, and limited public awareness about prevention. Vaxelis helps patients by providing immunity against hepatitis B through the inclusion of the hepatitis B surface antigen in its formulation, preventing infection and its associated complications. For instance, April 2025, according to Centers for Disease Control and Prevention, U.S-based government agency reported that, in 2023, there were 2,214 new cases of acute hepatitis B reported. Further, there were 1,769 hepatitis B-related deaths reported during 2023. Therefore, the increase in the prevalence of hepatitis B cases is driving the growth of the vaxelis industry. Rise in healthcare expenditure is expected to propel the growth of the vaxelis market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. Healthcare expenditure helps vaxelis by supporting vaccination programs, improving access to immunization, and funding public health initiatives that increase awareness and distribution of vaccines, thereby driving demand and adoption. For instance, in June 2025, according to Health Foundation, a UK-based independent charity, planned Department of Health and Social Care total spending is expected to grow from $265.4 billion (£215.6 billion) in cash terms in 2025/26 to $303.9 billion (£246.8 billion) in 2028/29, representing a real-terms increase of 2.8 percent per year. Thus, the rise in healthcare expenditure is driving the growth of the vaxelis industry.

Key Players In The Global Vaxelis Market

Major companies operating in the vaxelis market are Merck & Co. Inc., Sanofi S.A.

Regional Insights

North America was the largest region in the vaxelis market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vaxelis Market?

The vaxelis market consists of sales of active ingredients and antigens, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vaxelis Market Report 2026?

The vaxelis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vaxelis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.